MUL1 ELISA Kit (Human)

CVID12; DNA-binding factor KBF1; EBP-1; KBF1; NFkappaB; NF-kappaB; NF-kappa-B1; NF-kappabeta; NF-kB; NF-kB1; NFKB-p105; NFKB-p50; nuclear factor kappa-B DNA binding subunit; nuclear factor NF-kappa-B p105 subunit; nuclear factor NF-kappa-B p50 subunit; nuclear factor of kappa light polypeptide gene enhancer in B-cells 1.

NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.

Aviva Systems Biology MUL1 ELISA Kit (Human) (OKWB00235) is based on standard sandwich enzyme-linked immuno-sorbent assay technology. An antibody specific for MUL1 has been pre-coated onto a 96-well plate (12 x 8 Well Strips) . Standards or test samples are added to the wells, incubated and removed. A biotinylated detector antibody specific for MUL1 is added, incubated and followed by washing. Avidin-Peroxidase Conjugate is then added, incubated and unbound conjugate is washed away. An enzymatic reaction is produced through the addition of TMB substrate which is catalyzed by HRP generating a blue color product that changes to yellow after adding acidic stop solution. The density of yellow coloration read by absorbance at 450 nm is quantitatively proportional to the amount of sample MUL1 captured in the well.

Reconstitution & Storage Instructions Western Blotting/Immunoblotting (WB/IB) Protocol Immunohistochemistry (IHC) Protocol Immunocytochemistry (ICC) Protocol Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol Blocking Peptide Competition Protocol (BPCP) Immunoprecipitation (IP) Protocol Antibody Array (AA) Protocol Reconstitution & Storage Instructions Reconstitution & Storage Instructions Western Blotting/Immunoblotting (WB/IB) Protocol Western Blotting/Immunoblotting (WB/IB) Protocol Immunohistochemistry (IHC) Protocol Immunohistochemistry (IHC) Protocol Immunocytochemistry (ICC) Protocol Immunocytochemistry (ICC) Protocol Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol Blocking Peptide Competition Protocol (BPCP) Blocking Peptide Competition Protocol (BPCP) Immunoprecipitation (IP) Protocol Immunoprecipitation (IP) Protocol Antibody Array (AA) Protocol Antibody Array (AA) Protocol

Sample Type Range Mean Serum (n=5) 87-100 94 EDTA Plasma (n=5) 86-101 93 Heparin Plasma (n=5) 87-103 95 Sample Type Range Mean Sample Type Range Mean Serum (n=5) 87-100 94 Serum (n=5) 87-100 94 EDTA Plasma (n=5) 86-101 93 EDTA Plasma (n=5) 86-101 93 Heparin Plasma (n=5) 87-103 95 Heparin Plasma (n=5) 87-103 95

Component Amount MUL1 Microplate 96 Wells (12 x 8 Well strips) MUL1 Lyophilized Standard 2 x 20 ng 100X MUL1 Biotinylated Detector Anitbody 1 x 120 uL 100X Avidin-HRP Conjugate 1 x 120 uL Standard Diluent 1 x 20 mL Detector Antibody Diluent 1 x 12 mL Conjugate Diluent 1 x 12 mL 25X Wash Buffer 1 x 20 mL TMB Substrate 1 x 10 mL Stop Solution 1 x 10 mL Component Amount Component Amount MUL1 Microplate 96 Wells (12 x 8 Well strips) MUL1 Microplate 96 Wells (12 x 8 Well strips) MUL1 Lyophilized Standard 2 x 20 ng MUL1 Lyophilized Standard 2 x 20 ng 100X MUL1 Biotinylated Detector Anitbody 1 x 120 uL 100X MUL1 Biotinylated Detector Anitbody 1 x 120 uL 100X Avidin-HRP Conjugate 1 x 120 uL 100X Avidin-HRP Conjugate 1 x 120 uL Standard Diluent 1 x 20 mL Standard Diluent 1 x 20 mL Detector Antibody Diluent 1 x 12 mL Detector Antibody Diluent 1 x 12 mL Conjugate Diluent 1 x 12 mL Conjugate Diluent 1 x 12 mL 25X Wash Buffer 1 x 20 mL 25X Wash Buffer 1 x 20 mL TMB Substrate 1 x 10 mL TMB Substrate 1 x 10 mL Stop Solution 1 x 10 mL Stop Solution 1 x 10 mL